kyvernatx.com (KYTX) - Market Value to Book Value Ratio
The visualized price action of Kyverna Therapeutics (KYTX) shares on the GURU.Markets platform is based on a course toward global expansion through the scaling of CAR-T developments, with the current indicator standing at 2.14. Kyverna Therapeutics is reimagining oncological methods to restore immunity in severe pathologies. Additionally, the business aims to create definitive therapies for multiple sclerosis and systemic lupus erythematosus.
Kyverna Therapeutics Inc. (KYTX) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization indicators:
- book capitalization data:
- debt obligations and liquidity statistics:
- earnings and valuation multiples indicators:
Basic company analysis:Kyverna Therapeutics - KYTX
Kyverna Therapeutics' status as an innovator in cell therapy for autoimmune diseases determines the current market capitalization-to-book value ratio. This coefficient compares the business's market value with its net assets, demonstrating the level of investor confidence in the company's ability to convert scientific authority into capital and effectively counter rising operating expenses.
Competitor analysis
ARGX (argenx SE) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio BNTX|Market Value to Book Value Ratio abivax.com|ADMA Biologics Inc - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio PTGX|IMVT (Immunovant Therapeutics) - Market Value to Book Value|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|Market Capitalization to Book Value Ratio grifols.com GRFS|ADPT - Market Value to Book Value Ratio|Market Value to Book Value CLDX (Celldex Therapeutics Inc)|Aurinia Pharma (AUPH) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio BioCryst Corp|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com|Market Cap to Net Assets Ratio PHVS (Pharvaris)|ABCL (AbCellera Biologics) - Market Value to Book Value|Market Capitalization to Book Value Ratio TRML (Tourmaline Corp)|Market Capitalization to Book Value Precigen Corp (PGEN)|PHAR - Market Value to Book Value Ratio|nektar.com (NKTR) - Market Cap to Net Assets Ratio|Upstream Bio (UPB) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|Market Cap to Net Assets Ratio IMNM|Market Capitalization to Book Value Ratio Gossamer Bio Corp.|Market Value to Book Value Ratio KalVista Pharmaceuticals (KALV)|septerna.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio PVLA (Pieris Pharmaceuticals, Inc.)|Savara Inc (SVRA) - Market-to-Book Ratio|RIGL - Market Value to Book Value Ratio|ANAB - Market Capitalization to Book Value Ratio|ATXS (Astria Therapeutics) - Market Cap to Net Assets Ratio|Market-to-Book Ratio engene.com (ENGN)|Market Cap to Net Assets Ratio RAPT|Market Value to Book Value Ratio JBIO|Market Capitalization to Book Value Ratio ACRS|TLSA - Market-to-Book Ratio|Market Value to Book Value Ratio Cabaletta Bio, Inc. CABA|Market Value to Book Value VTYX|THTX - Market Value to Book Value Ratio|AVTX (Avalo Therapeutics, Inc.) - Capitalization to Book Value Ratio|ELDN: Market Capitalization to Book Value Ratio|Agenus, Inc (AGEN) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio CLYM|ZURA: Market Value to Book Value|Market Cap to Net Assets Ratio ATYR (aTyr Pharma)|Market Cap to Book Value Multiple ADAG|Market Capitalization to Book Value Ratio IMA (Ikena Oncology)|Market Value to Book Value STTK|Equillium Bio - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Connect Biopharma|immunic-therapeutics.com (IMUX) - Market Value to Book Value Ratio|Atara Bio - Market Value to Book Value|IFRX (InflaRx NV) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio X4 Pharmaceuticals, Inc|Market Value to Book Value Ratio Adicet Bio (ACET)|CELU: Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio INMB (INmune Bio)|Barinthus Biotherapeutics PLC (BRNS) - Market-to-Book Ratio|KZR: Market Cap to Net Assets Ratio|SABS - Market Capitalization to Book Value Ratio|AKTX (Akari Therapeutics) - Market Cap to Net Assets Ratio|ENLV: Market Cap to Book Value Multiple|QTTB (Q32 Bio Inc) - Market Capitalization to Book Value Ratio|GeoVax Labs (GOVX) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio EDSA|Market Cap to Net Assets Ratio iBio Corporation IBIO|Market Value to Book Value Ratio Carisma Therapeutics Inc. CARM|Market Capitalization to Book Value xtlbio.com (XTLB)|BOLT - Market Value to Book Value Ratio|HCWB - Market Capitalization to Book Value Ratio|APVO (aptevotherapeutics.com) - Market Cap to Net Assets Ratio|Market-to-Book Ratio aimimmuno.com (AIM)|Market Cap to Net Assets Ratio ADTX|GRI (gribio.com) - Market Cap to Book Value Multiple|Market Cap to Net Assets Ratio XRTX (XORTX Therapeutics)|Vyome Holdings Inc. - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Revelation Bio REVB|INDP (Indaptus Corp) - Market Capitalization to Net Assets|Scinai Immunotherapeutics - Market Capitalization to Book Value Ratio|Market Value to Book Value CALI (CalciMedica, Inc.)|AFMD: Market Capitalization to Book Value Ratio|Allakos (ALLK) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio HOOKIPA Pharma, Inc.|IGMS: Market Value to Book Value|Market Value to Book Value Ratio iTeos Therapeutics (ITOS)|Market Cap to Net Assets Ratio oceanbiomedical.com OCEA|Market Capitalization to Book Value Ratio TCBP (TC BioPharm)|Market Capitalization to Book Value Ratio Third Harmonic Bio Inc. THRD